At Novartis, our long-standing commitment to patients living with chronic myeloid leukemia (CML) spans more than two decades, marked by breakthroughs that have helped turn what was once a life-limiting condition into a chronic one for many. Yet, there's more ground to cover. Despite advancements, many patients still face hurdles such as lower response rates, treatment resistance, and intolerance, and have poor quality of life. That’s why we’re committed to continuing to pioneer targeted treatments for CML, and ensuring every patient has access to innovative medicines. Learn more here: https://lnkd.in/gadSYVJg
Pioneering solutions for patients with CML
Thank you for your unwavering commitment to patients living with chronic myeloid leukemia (CML), Novartis. Your dedication to pioneering targeted treatments and ensuring access to innovative medicines is truly commendable. Together, we can strive for better outcomes and improved quality of life for all patients. #CML #InnovativeMedicines #PatientCare
Love to see that we are improving life of our patients
Sağlık ve mutlulukla iyi bayramlar...
Me siento muy orgulloso de haber crecido con Novartis. Visitador Medico
dentist@jimbaran bali
1wBPJS Health Insurance Indonesia will cover all treatment CML patients...